Strontium, a calcium-like mineral, is taken as a prescription drug or supplement for bone health. Prescription strontium has strong evidence for fewer spine fractures, some reduction in other fractures, and moderate evidence for slower knee joint wear; supplements have no fracture evidence. Main risks: blood clots, well documented in trials, and heart attacks, where studies disagree; harm appears concentrated in people with heart or vessel disease or reduced mobility. (Full Review)

Protocol

Conventional prescription regimen

Strontium ranelate 2 g once daily

Sachet in water (about 680 mg elemental strontium); restricted since 2014 to people without cardiovascular disease who cannot use other osteoporosis drugs

Integrative supplement regimen

Strontium citrate, 340–680 mg elemental strontium daily

Untested for fractures

Time of day

Bedtime

At least 2 hours after the last meal and away from calcium, which maximizes absorption

Time to effect

Vertebral fracture reduction

Within the first year

Shown with strontium ranelate

Slower knee joint-space loss

Over 3 years

Slower loss of joint-space width on X-ray

Bone density rise

Within months

Much of that early rise is scanning artifact

Benefits

High: Fewer osteoporotic fractures

Medium: Slower knee osteoarthritis progression

Low: Relief of dentin hypersensitivity; reduced skin itch and irritation; longer healthy lifespan

Speculative: Reduced inflammation and metabolic risk; better dental implant anchoring

Contraindications

Current or previous venous thromboembolism (deep vein thrombosis or pulmonary embolism)

Temporary or permanent immobilization (e.g., post-surgical bed rest, wheelchair use)

Established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease (prior stroke or transient ischemic attack)

Uncontrolled high blood pressure (persistently ≥140/90 mmHg despite treatment)

Severe kidney impairment (creatinine clearance <30 mL/min)

Prior DRESS, Stevens-Johnson syndrome, or other severe rash on strontium

Pregnancy, breastfeeding, children and adolescents with growing skeletons

Phenylketonuria (for ranelate sachets sweetened with aspartame)

Key Interactions

Tetracycline and quinolone antibiotics (doxycycline, minocycline, ciprofloxacin, levofloxacin): avoid co-administration

Calcium-containing products and dairy (calcium carbonate, calcium citrate, milk): reduce strontium absorption by roughly 60–70%

Over-the-counter aluminum or magnesium hydroxide antacids (Maalox, Mylanta): reduce strontium absorption

Estrogen-containing therapies and selective estrogen receptor modulators (estradiol, raloxifene, tamoxifen): additive clot risk

Mineral supplements (iron, zinc, magnesium): compete with strontium for absorption

Additive bone supplements (vitamin D3, vitamin K2, magnesium): generally compatible

Other interventions (bone density scans, calcium blood tests, surgery, long-haul travel): inflated scan results, possible calcium assay interference, immobility clot risk

Risk & Side Effects

High: Venous thromboembolism; gastrointestinal upset

Medium: Heart attack and cardiovascular death; neurological adverse events

Low: Severe skin hypersensitivity reactions; impaired bone mineralization at high exposure; inflated bone density readings

Monitoring

Marker	Target	Why
Bone mineral density (DXA spine and hip)	T-score ≥ −1.0; stable or rising after strontium correction	Tracks bone status
Serum 25-hydroxyvitamin D	40–60 ng/mL	Supports calcium absorption
Serum calcium	9.2–10.0 mg/dL	Screens calcium balance
Creatinine clearance / eGFR	eGFR >60 mL/min/1.73 m²	Strontium is kidney-cleared
Blood pressure	<120/80 mmHg	Cardiovascular risk
Apolipoprotein B (ApoB)	<80 mg/dL	Cardiovascular risk
CTX and P1NP	No established target; track change from own baseline	Bone turnover response
Eosinophil count (if rash)	<500 cells/µL	Screens for DRESS

Cadence: Baseline before starting; blood pressure and symptom review at 1 and 3 months, then every 6 months; kidney function, vitamin D, and calcium every 6–12 months; bone turnover markers at 3–6 months; bone density scan every 1–2 years on the same scanner, with strontium correction noted.

Qualitative Assessment

New back pain, height loss, or fractures
Calf pain, leg swelling, or sudden breathlessness
Chest pain or exertional discomfort
Skin rash, fever, or swollen glands
Bowel tolerance in the first 3 months
Knee pain, stiffness, and walking ability

Strontium for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment